![Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis - The Lancet Psychiatry Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis - The Lancet Psychiatry](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/4b095de3-d6ee-4bb7-ad47-cf56a22b1ac1/gr1.gif)
Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis - The Lancet Psychiatry
![Vitamin-mineral treatment of attention-deficit hyperactivity disorder in adults: double-blind randomized placebo-controlled trial – Micronutrients Research Vitamin-mineral treatment of attention-deficit hyperactivity disorder in adults: double-blind randomized placebo-controlled trial – Micronutrients Research](https://micronutrientsresearch.com/wp-content/uploads/2019/06/Vitamin-mineral-treatment-of-attention-deficit-hyperactivity-disorder-in-adults-double-blind-randomised-placebo-controlled-trial.png)
Vitamin-mineral treatment of attention-deficit hyperactivity disorder in adults: double-blind randomized placebo-controlled trial – Micronutrients Research
![Druggable genome in attention deficit/hyperactivity disorder and its co-morbid conditions. New avenues for treatment | Molecular Psychiatry Druggable genome in attention deficit/hyperactivity disorder and its co-morbid conditions. New avenues for treatment | Molecular Psychiatry](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41380-019-0540-z/MediaObjects/41380_2019_540_Fig1_HTML.png)
Druggable genome in attention deficit/hyperactivity disorder and its co-morbid conditions. New avenues for treatment | Molecular Psychiatry
![Efficacy and Safety of Medication for Attention-Deficit Hyperactivity Disorder in Children and Adolescents with Common Comorbidities: A Systematic Review | SpringerLink Efficacy and Safety of Medication for Attention-Deficit Hyperactivity Disorder in Children and Adolescents with Common Comorbidities: A Systematic Review | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40120-021-00249-0/MediaObjects/40120_2021_249_Fig1_HTML.png)
Efficacy and Safety of Medication for Attention-Deficit Hyperactivity Disorder in Children and Adolescents with Common Comorbidities: A Systematic Review | SpringerLink
PLOS ONE: Gastrointestinal adverse events during methylphenidate treatment of children and adolescents with attention deficit hyperactivity disorder: A systematic review with meta-analysis and Trial Sequential Analysis of randomised clinical trials
![Clinical trials were missing from regulatory documents of extended-release methylphenidate for ADHD in adults: a case study of public documents - ScienceDirect Clinical trials were missing from regulatory documents of extended-release methylphenidate for ADHD in adults: a case study of public documents - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0895435621003516-gr1.jpg)
Clinical trials were missing from regulatory documents of extended-release methylphenidate for ADHD in adults: a case study of public documents - ScienceDirect
![Introduction. Adult ADHD in the Real World: From Clinical Trials to Clinical Practice. - ppt download Introduction. Adult ADHD in the Real World: From Clinical Trials to Clinical Practice. - ppt download](https://slideplayer.com/12460278/74/images/slide_1.jpg)
Introduction. Adult ADHD in the Real World: From Clinical Trials to Clinical Practice. - ppt download
![A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial - The Lancet Digital Health A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial - The Lancet Digital Health](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/cb5704da-3b50-4f12-b83b-1a4fa653c119/gr1.gif)